Expert Reviews Importance of BRCA Testing in Ovarian Cancer

Testing for BRCA mutations is an important step in developing the treatment plan for patients with breast cancer, says Leslie Randall. 
BY GREG KENNELTY
PUBLISHED: JUNE 27, 2016
For patients with ovarian cancer, early identification of BRCA mutations will significantly help in determining a treatment plan, says Leslie Randall.  

In an interview with CURE, Randall, associate professor, gynecology/ oncology, University of California Irvine, discusses the importance of BRCA testing and the generally accepted guidelines for these tests. She says the tests are strongly recommended for all patients with ovarian cancer.  

What is the importance of early BRCA testing?

Early BRCA testing is very important for several reasons, the most of which is identifying patients who have a specific tumor biology. Patients with BRCA mutations tend to be more platinum-sensitive than patients who don't have those mutations. They're also eligible for different clinical trials than patients who don't have those mutations.   

In addition to that, identifying these patients will identify them for later on in their treatment line for things like PARP inhibitor therapy, as well as identify those whose family members should maybe be tested for genetic mutations.   

What are the current recommendations for BRCA testing?

BRCA testing is recommended for all of our invasive ovarian cancer patients to include fallopian tube and peritoneal cancer. Those guidelines are endorsed by the NCCN, ASCO, the Society of Gynecologic Oncology, SGO, National Genetic Counselor’s Society and also the American Congress of Obstetrics and Gynecology. All of these come together in what we called the Genetic Summit to discuss how strongly we recommend BRCA testing in our ovarian cancer patients.   

We all strongly recommend it, and are somewhat disenchanted that it hasn't been happening at the rates we would like to see, though I think it was significantly improved within the last year.   

The level of evidence to support it is about a Level B if you look at the Preventative Taskforce Levels of Evidence.   

How prevalent are BRCA mutations in patients with ovarian cancer?

I always say that the more we test, the more we'll learn that more patients have it. Currently, we think the prevalence of BRCA mutations in ovarian cancer patients is about 20 percent.   
 

What is the difference in terms of germline versus somatic BRCA alterations, and is one more important than the other?


Germline and somatic mutations are both important. Germline mutations are the ones that are inherited, so you're born with a germ-line mutation in BRCA1 you can pass that on to your offspring. Somatic mutations happen only in the tumor. Somatic mutations can't be inherited, they can't be passed on to future generations, so that's the very important distinction between germline and somatic mutations.    

I think they're both important because they are both associated with responses to BRCA-specific therapies like PARP inhibition.

Talk about this article with other patients, caregivers, and advocates in the Ovarian Cancer CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
Can Treatment at a Large Cancer Center Mitigate Racial Disparities in Ovarian Cancer?
Studies have shown that African American women tend to have worse outcomes after ovarian cancer surgery than their white counterparts. 
New Maintenance Therapy for Ovarian Cancer Seeks FDA Approval
The pharmaceutical company Clovis Oncology filed a supplemental new drug application (sNDA) to the FDA for their drug Rubraca (rucaparib) to be used as maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Better Understanding of Ovarian Cancer Is Needed, Expert Says
To better understand ovarian cancer, as well as predict when women might relapse, it is crucial that researchers start investigating more of the molecular phases of the disease, says Peter Dottino, M.D.
Related Videos
Expert Discusses Exciting Advances in Ovarian Cancer
Rebecca Arend, M.D., gynecologic oncologist at University of Alabama at Birmingham Hospital, discusses the rapidly changing field of ovarian cancer. 
The Importance of Seeing an Ovarian Cancer Specialist
Renee Cowan, gynecologic oncology fellow at Memorial Sloan Kettering Cancer Center (MSK), discusses the importance of patients with ovarian cancer seeing an oncologist who specializes in the field.  
Dr. Boulay Discusses Removing a 140-Pound Tumor
Richard Boulay, M.D., chief of the division of Gynecologic Oncology at the Lehigh Valley Health Netowrk, tells the story of removing a 140-pound tumor from Mary Clancy. The tumor had been growing for at least 10 years when it was caught by a CAT scan, and was about half her body weight.
x
//For side ad protocol